Precigen (PGEN) Share-based Compensation (2012 - 2026)
Precigen (PGEN) posted quarterly Share-based Compensation of $146000.0 for Q1 2026, down 94.55% year-over-year from $2.7 million in Q1 2025, and down 93.25% quarter-over-quarter from $2.2 million in Q4 2025.
Precigen (PGEN) Share-based Compensation (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Share-based Compensation for 15 consecutive years, with $146000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 94.55% year-over-year to $146000.0; the TTM figure through Mar 2026 stood at $8.3 million (down 12.88% YoY), while the FY2025 annual figure was $10.9 million, up 14.73% from the prior year.
- Share-based Compensation fell to $146000.0 in Q1 2026 per PGEN's latest filing, from $2.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q3 2025 and bottomed at -$7.6 million in Q4 2023.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $2.3 million in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 445.07% — and 2024, when it surged 186.47%.
- Precigen's Share-based Compensation stood at $2.2 million in 2022, then sank by 445.07% to -$7.6 million in 2023, then surged by 137.57% to $2.9 million in 2024, then decreased by 24.5% to $2.2 million in 2025, then sank by 93.25% to $146000.0 in 2026.
- Business Quant data shows PGEN's Share-based Compensation at $146000.0 in Q1 2026, $2.2 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Mn |
| Jun 30, 2026 | 3.58 Mn |
| Mar 31, 2026 | 146,000.00 |
| Mar 31, 2026 | 146,000.00 |
| Dec 31, 2025 | 2.16 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | -901,000.00 |
| Jun 30, 2025 | -901,000.00 |
| Mar 31, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 6.61 Mn |
| Sep 30, 2024 | 6.61 Mn |
| Jun 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -2.58 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.58 Mn |